Crossmark Global Holdings Inc. bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,666 shares of the company’s stock, valued at approximately $286,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Teacher Retirement System of Texas lifted its stake in Neurocrine Biosciences by 0.8% during the second quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock valued at $320,000 after purchasing an additional 57 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares during the last quarter. Utah Retirement Systems lifted its stake in Neurocrine Biosciences by 1.9% during the second quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock valued at $736,000 after purchasing an additional 300 shares during the last quarter. Aperio Group LLC lifted its stake in Neurocrine Biosciences by 3.7% during the second quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock valued at $1,027,000 after purchasing an additional 789 shares during the last quarter. Finally, Grandfield & Dodd LLC lifted its stake in Neurocrine Biosciences by 15.2% during the second quarter. Grandfield & Dodd LLC now owns 6,130 shares of the company’s stock valued at $282,000 after purchasing an additional 810 shares during the last quarter.

In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 30,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the sale, the insider now owns 77,691 shares in the company, valued at approximately $5,794,194.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Darin Lippoldt sold 9,900 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total transaction of $723,195.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 150,710 shares of company stock valued at $9,758,593. Insiders own 4.80% of the company’s stock.

Shares of Neurocrine Biosciences, Inc. (NBIX) opened at $68.40 on Thursday. Neurocrine Biosciences, Inc. has a 12-month low of $37.35 and a 12-month high of $75.98. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same quarter in the previous year, the company earned ($0.43) EPS. equities research analysts expect that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current fiscal year.

NBIX has been the subject of several research analyst reports. Oppenheimer restated a “buy” rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, September 7th. BMO Capital Markets upped their price target on shares of Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Jefferies Group restated a “buy” rating and issued a $69.00 price target (up previously from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Needham & Company LLC restated a “buy” rating and issued a $86.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $78.88.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/30/crossmark-global-holdings-inc-buys-shares-of-4666-neurocrine-biosciences-inc-nbix.html.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.